



Product Information

Product ID C1613

CAS No. 288383-20-0

Chemical Name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline

Synonym AZD2171

Formula C₂₅H₂₇FN₄O₃

Formula Wt. 450.51

Melting Point


Purity ≥98%

Solubility DMSO to 90 mg/ml

Store Temp Ambient

Ship Temp Ambient

Description Cediranib is a pan-VEGFR inhibitor that displays anticancer chemotherapeutic and anti-angiogenic activities. Cediranib is currently in clinical trials and displays activity against a wide variety of cancers. In an animal model of intestinal cancer, cediranib decreases lesion number and polyp size, and in a separate animal model of brain metastasis, cediranib decreases tumor vascular bed volume.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
C1613	25 mg	\$132.50
C1613	100 mg	\$376.70
C1613	250 mg	\$753.70

References Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013 Jun 20;31(18):2296-302. PMID: 23630200.

JuanYin J, Tracy K, Zhang L, et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis. 2009;26(5):403-14. PMID: 19277878.

Goodlad RA, Ryan AJ, Wedge SR, et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis. 2006 Oct;27(10):2133-9. PMID: 16782971.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.